Timing clarification: Edwards reports today, Thursday, July 23, 2026, after the market closes—not tomorrow. The conference call begins at 5:00 p.m. ET. (edwards.com)
The central question is not whether Edwards can meet its Q2 guidance—the Street is already near the midpoint—but whether the strong Q1 trends are durable enough to support another increase in full-year expectations.
The most important variables are:
A modest headline beat without stronger guidance could be treated as merely in line. A convincing print would likely require broad-based revenue upside, approximately double-digit TAVR growth, continued TMTT acceleration and evidence that margin leverage is operational rather than spending-related.
| Metric | Q2 company guidance | Street expectation |
|---|---|---|
| Revenue | $1.66B–$1.74B | Approximately $1.70B |
| Adjusted EPS | $0.70–$0.76 | Approximately $0.73–$0.74 |
| TAVR revenue growth | No quarterly target | Approximately 9.1% |
| TMTT revenue growth | No quarterly target | Approximately 39.3% |
| Surgical revenue growth | No quarterly target | Approximately 4.1% |
The segment growth estimates translate to roughly $1.23 billion of TAVR sales, $187 million of TMTT sales and $278 million of Surgical sales. (zacks.com)
Current full-year guidance calls for:
Edwards raised both sales and EPS guidance after Q1, when revenue reached $1.65 billion, constant-currency growth was 12.7%, and adjusted EPS was $0.78. (ir.edwards.com)
TAVR accounted for approximately 73% of Q1 sales, making it the principal determinant of the quarter.
Q1 TAVR sales were $1.20 billion, up 11% at constant currency. Management attributed most of the performance to market growth, with some competitive benefit from a rival’s European exit and slight share improvement in the United States. Edwards subsequently raised full-year TAVR guidance to 7%–9%. (edwards.com)
The Street’s approximately 9.1% TAVR growth estimate looks achievable after Q1’s 11%, but the market may require growth near or above 10% to view the quarter as a clear positive.
On June 15, CMS proposed major changes to Medicare’s TAVR coverage framework. The proposal would remove coverage-with-evidence-development requirements for symptomatic severe aortic stenosis, provide coverage for asymptomatic severe disease within approved studies, simplify patient evaluation and eliminate hospital-level procedural-volume requirements in favor of operator-level standards. CMS would also permit a single qualified TAVR operator rather than requiring joint intraoperative participation. (cms.gov)
This is potentially constructive for:
However, it should be viewed primarily as a 2027-and-beyond catalyst, not a material contributor to Q2 revenue. The second comment period ended July 15, and the proposal is not yet the final coverage decision. Investors should listen for management’s assessment of the likely final language, timing and potential impact on center expansion and patient access.
TMTT is the company’s most important incremental growth engine. Q1 sales reached approximately $173 million, rising about 42% at constant currency, driven by EVOQUE, PASCAL and the initial SAPIEN M3 launch.
The Street expects approximately $187 million in Q2, or 39% growth. That would be a solid result, but only modest sequential growth from Q1.
At the consensus estimate, first-half TMTT sales would be about $360 million. Edwards would then need roughly $380 million–$420 million in the second half to reach its $740 million–$780 million full-year range. That requirement appears manageable, but it assumes continued center expansion and stronger contributions from newer products.
A TMTT result above approximately $190 million, accompanied by unchanged or improved launch timelines, would strengthen the case that the business can exceed the upper end of full-year guidance.
Q1 adjusted operating margin was 31.4%, but management explicitly said it benefited from better sales and the planned phasing of strategic investments. Full-year guidance remains at the high end of 28%–29%, while R&D is expected to represent approximately 17% of sales.
That creates an important distinction:
Investors should expect some sequential margin normalization as Edwards funds clinical programs, manufacturing capacity and commercialization of TMTT products. Holding or raising full-year margin guidance while maintaining investment would be more valuable than an isolated Q2 EPS beat.
This will also be the first earnings cycle with Doretta Mistras as CFO. She succeeded longtime CFO Scott Ullem at the end of May, so commentary around capital allocation, margin expansion and investment priorities will receive additional attention. (ir.edwards.com)
Several developments could influence the medium-term outlook:
These are unlikely to drive Q2 numbers but are central to whether Edwards can sustain approximately 10% annual sales growth beyond 2026.
In July, Edwards agreed to pay a $10 million civil penalty to settle FTC allegations that its JC Medical acquisition did not comply with Hart-Scott-Rodino pre-merger filing requirements. The financial amount is immaterial relative to Edwards’ earnings and cash position, but the associated prior-notice provisions could modestly complicate future transaction activity. (ftc.gov)
This should not be an earnings driver unless management identifies additional legal costs or strategic restrictions.
EW enters the report with a solid fundamental setup but a reasonably demanding bar. Q1 already established strong TAVR and TMTT momentum and produced an initial guidance increase. As a result, simply landing at the midpoint of Q2 guidance may not be enough.
The most constructive result would show that TAVR remains near double-digit growth, TMTT is scaling sequentially, and Edwards can preserve full-year margin leverage while funding its pipeline. More than the headline EPS figure, management’s guidance and commentary on U.S. TAVR demand, TMTT center expansion and the CMS proposal are likely to determine the stock’s reaction.